Yupelri, an oral medicine for tardive dyskinesia and Tourette syndrome, received FDA approval for these indications in 2023 [1]. Its FDA label outlines specific usage and safety information for healthcare professionals and patients.
What are the approved uses for Yupelri?
Yupelri is indicated for the treatment of tardive dyskinesia in adults and Tourette syndrome in pediatric patients aged 13 years and older [1].
What is the recommended dosage for Yupelri?
The recommended starting dosage for Yupelri is 10 mg taken orally once daily. The dosage can be increased to 20 mg orally once daily, or further to 30 mg orally once daily, based on individual patient response and tolerability [1].
What are the potential side effects of Yupelri?
Common side effects associated with Yupelri include sedation, dizziness, dry mouth, constipation, blurred vision, and weight gain [1]. It is important for patients to discuss any concerns about side effects with their healthcare provider.
Are there any contraindications for Yupelri?
Yupelri is contraindicated in patients with known hypersensitivity to risperidone, the active ingredient in Yupelri, or to any of its components [1].
What safety precautions should be considered with Yupelri?
Healthcare providers should monitor patients for somnolence and potential risks associated with increased somnolence, such as impaired driving or operating heavy machinery. The label also advises caution when Yupelri is taken with other central nervous system depressants [1].
How does Yupelri compare to other treatments for tardive dyskinesia or Tourette syndrome?
Yupelri offers an oral treatment option for tardive dyskinesia and Tourette syndrome. The choice of treatment often depends on the specific patient's condition, other medications they may be taking, and their tolerance for different therapeutic approaches [1].
When does Yupelri's patent expire?
Information regarding the specific patent expiry for Yupelri is available through resources like DrugPatentWatch.com [2]. This information is crucial for understanding market exclusivity and the potential for generic or biosimilar competition in the future.